Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases — by reprogramming patients’ out-of-whack immune ...
The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...
Pharmaceutical Technology on MSN
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Sanofi's $2.56bn bispecific autoimmune deal with Earendil Labs is the second in recent history, and will bolster the French ...
VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The midstage MoonStone study saw 116 ...
A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...
CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncology and ...
Enlaza Therapeutics ("Enlaza" or the "Company"), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals ("Vertex") ...
Read full article: After Sydney shooting, Detroit’s Jewish community emphasizes love, strength for Hanukkah Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback